Cargando…
Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate
We previously generated fully human antibody-producing TC-mAb mice for obtaining potential therapeutic monoclonal antibodies (mAbs). In this study, we investigated 377 clones of fully human mAbs against a tumor antigen, epithelial cell adhesion molecule (EpCAM), to determine their antigen binding pr...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015092/ https://www.ncbi.nlm.nih.gov/pubmed/36918661 http://dx.doi.org/10.1038/s41598-023-31263-x |
_version_ | 1784907141581111296 |
---|---|
author | Satofuka, Hiroyuki Wang, Yayan Yamazaki, Kyotaro Hamamichi, Shusei Fukuhara, Takeshi Rafique, Abdur Osako, Nana Kanazawa, Iori Endo, Takeshi Miyake, Naomi Honma, Kazuhisa Nagashima, Yuichi Hichiwa, Genki Shimoya, Kazuto Abe, Satoshi Moriwaki, Takashi Murakami, Yasufumi Gao, Xu Kugoh, Hiroyuki Oshimura, Mitsuo Ito, Yuji Kazuki, Yasuhiro |
author_facet | Satofuka, Hiroyuki Wang, Yayan Yamazaki, Kyotaro Hamamichi, Shusei Fukuhara, Takeshi Rafique, Abdur Osako, Nana Kanazawa, Iori Endo, Takeshi Miyake, Naomi Honma, Kazuhisa Nagashima, Yuichi Hichiwa, Genki Shimoya, Kazuto Abe, Satoshi Moriwaki, Takashi Murakami, Yasufumi Gao, Xu Kugoh, Hiroyuki Oshimura, Mitsuo Ito, Yuji Kazuki, Yasuhiro |
author_sort | Satofuka, Hiroyuki |
collection | PubMed |
description | We previously generated fully human antibody-producing TC-mAb mice for obtaining potential therapeutic monoclonal antibodies (mAbs). In this study, we investigated 377 clones of fully human mAbs against a tumor antigen, epithelial cell adhesion molecule (EpCAM), to determine their antigen binding properties. We revealed that a wide variety of mAbs against EpCAM can be obtained from TC-mAb mice by the combination of epitope mapping analysis of mAbs to EpCAM and native conformational recognition analysis. Analysis of 72 mAbs reacting with the native form of EpCAM indicated that the EpCL region (amino acids 24–80) is more antigenic than the EpRE region (81–265), consistent with numerous previous studies. To evaluate the potential of mAbs against antibody–drug conjugates, mAbs were directly labeled with DM1, a maytansine derivative, using an affinity peptide-based chemical conjugation (CCAP) method. The cytotoxicity of the conjugates against a human colon cancer cell line could be clearly detected with high-affinity as well as low-affinity mAbs by the CCAP method, suggesting the advantage of this method. Thus, this study demonstrated that TC-mAb mice can provide a wide variety of antibodies and revealed an effective way of identifying candidates for fully human ADC therapeutics. |
format | Online Article Text |
id | pubmed-10015092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100150922023-03-16 Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate Satofuka, Hiroyuki Wang, Yayan Yamazaki, Kyotaro Hamamichi, Shusei Fukuhara, Takeshi Rafique, Abdur Osako, Nana Kanazawa, Iori Endo, Takeshi Miyake, Naomi Honma, Kazuhisa Nagashima, Yuichi Hichiwa, Genki Shimoya, Kazuto Abe, Satoshi Moriwaki, Takashi Murakami, Yasufumi Gao, Xu Kugoh, Hiroyuki Oshimura, Mitsuo Ito, Yuji Kazuki, Yasuhiro Sci Rep Article We previously generated fully human antibody-producing TC-mAb mice for obtaining potential therapeutic monoclonal antibodies (mAbs). In this study, we investigated 377 clones of fully human mAbs against a tumor antigen, epithelial cell adhesion molecule (EpCAM), to determine their antigen binding properties. We revealed that a wide variety of mAbs against EpCAM can be obtained from TC-mAb mice by the combination of epitope mapping analysis of mAbs to EpCAM and native conformational recognition analysis. Analysis of 72 mAbs reacting with the native form of EpCAM indicated that the EpCL region (amino acids 24–80) is more antigenic than the EpRE region (81–265), consistent with numerous previous studies. To evaluate the potential of mAbs against antibody–drug conjugates, mAbs were directly labeled with DM1, a maytansine derivative, using an affinity peptide-based chemical conjugation (CCAP) method. The cytotoxicity of the conjugates against a human colon cancer cell line could be clearly detected with high-affinity as well as low-affinity mAbs by the CCAP method, suggesting the advantage of this method. Thus, this study demonstrated that TC-mAb mice can provide a wide variety of antibodies and revealed an effective way of identifying candidates for fully human ADC therapeutics. Nature Publishing Group UK 2023-03-14 /pmc/articles/PMC10015092/ /pubmed/36918661 http://dx.doi.org/10.1038/s41598-023-31263-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Satofuka, Hiroyuki Wang, Yayan Yamazaki, Kyotaro Hamamichi, Shusei Fukuhara, Takeshi Rafique, Abdur Osako, Nana Kanazawa, Iori Endo, Takeshi Miyake, Naomi Honma, Kazuhisa Nagashima, Yuichi Hichiwa, Genki Shimoya, Kazuto Abe, Satoshi Moriwaki, Takashi Murakami, Yasufumi Gao, Xu Kugoh, Hiroyuki Oshimura, Mitsuo Ito, Yuji Kazuki, Yasuhiro Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate |
title | Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate |
title_full | Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate |
title_fullStr | Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate |
title_full_unstemmed | Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate |
title_short | Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate |
title_sort | characterization of human anti-epcam antibodies for developing an antibody–drug conjugate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015092/ https://www.ncbi.nlm.nih.gov/pubmed/36918661 http://dx.doi.org/10.1038/s41598-023-31263-x |
work_keys_str_mv | AT satofukahiroyuki characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT wangyayan characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT yamazakikyotaro characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT hamamichishusei characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT fukuharatakeshi characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT rafiqueabdur characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT osakonana characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT kanazawaiori characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT endotakeshi characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT miyakenaomi characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT honmakazuhisa characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT nagashimayuichi characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT hichiwagenki characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT shimoyakazuto characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT abesatoshi characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT moriwakitakashi characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT murakamiyasufumi characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT gaoxu characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT kugohhiroyuki characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT oshimuramitsuo characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT itoyuji characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate AT kazukiyasuhiro characterizationofhumanantiepcamantibodiesfordevelopinganantibodydrugconjugate |